BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: 11.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.285

03 Jul
2026

-0.005

OPEN

$0.30

-1.72%

HIGH

$0.31

165,997

LOW

$0.29

TARGET
$0.75 163.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 0.1 1.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 25.5 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx0.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx18.4 M
Book Value Per Share xxxxxxxxxxxxxxx2.1
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.8 M
Net Profit Margin xxxxxxxxxxxxxxx1.17 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx5.66 %
Return on Invested Capital xxxxxxxxxxxxxxx5.51 %
Return on Assets xxxxxxxxxxxxxxx2.12 %
Return on Equity xxxxxxxxxxxxxxx5.66 %
Return on Total Capital xxxxxxxxxxxxxxx0.61 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-2.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx3 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx21.47

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.2 M
Capex % of Sales xxxxxxxxxxxxxxx1.09 %
Cost of Goods Sold xxxxxxxxxxxxxxx7 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

02/07/2026

1

Buy

$0.75

163.16%

Biome Australia announced its FY26 trading update with sales expected to be around $23.9m, a rise of 30% y/y but below Bell Potter's forecast of around $25.6m.

Contrary to historical skew, 2H sales growth will be lower than 1H sales growth with both international and domestic coming in under expectations.

Management pointed to a challenging environment with pharmacy wholesaling not managing to meet retail demand. Biome Australia has been lowering inventory levels.

The analyst questions whether cost inflation is weighing on wholesalers.

Biome reiterated its Vision 27 sales guidance of three-year cumulative sales of around $75m-plus. The broker has downgraded its FY27 sales forecast to align with guidance, which results in earnings forecasts being lower also for FY27/FY28.

Target price slips to 75c from $1.00 with no change in Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.10 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

1
FNArena Corporate Results Monitor – 24-02-2026

Feb 24 2026 - Australia
2
Rudi’s View: Pre-February Top Picks & Favourites

Jan 15 2026 - Rudi's View
3
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
4
Rudi’s View: Best Ideas & Conviction Calls

Feb 20 2025 - Rudi's View
5
FNArena Corporate Results Monitor – 19-02-2025

Feb 19 2025 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
2
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
3
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
4
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
5
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
6
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
7
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
8
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
9
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
10
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals